Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | BCL9 | O00512 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16694536 | 0.99 | ALDH1A1 (0.47) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL30391037 | 0.92 | CYP1A2 (0.48) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL20625250 | 0.87 | GAA (0.51) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL2830265 | 0.86 | CYP1A2 (0.52) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL2803614 | 0.85 | CYP1A2 (0.49) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL2722317 | 0.85 | CYP1A2 (0.49) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL16694716 | 0.84 | HTT (0.50) | ALDH1A1POLBCYP1A2CYP2D6L3MBTL1 | |
| SCHEMBL3285385 | 0.83 | CYP1A2 (0.51) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL1560458 | 0.83 | CYP1A2 (0.51) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL21498615 | 0.83 | POLB (0.69) | POLBCYP2C9CYP2C19CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801553-B1 | PRODRUGS OF FULVESTRANT | KASHIV BIOSCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4556480-A1 | COMPOUNDS CONSTITUTING C20-MODIFIED SALINOMYCIN DERIVATIVES, A METHOD FOR OBTAINING THE SAME, A COMPOSITION CONTAINING THE SAME AND A USE OF SAID COMPOUNDS | Fileclo Spolka Z Ograniczona Odpowiedzialnoscia (PL) | 2025-05-21 | — | — | EP | disclosed |
| US-20240294541-A1 | COMPOUNDS CONSTITUTING C20-MODIFIED SALINOMYCIN DERIVATIVES, A METHOD FOR OBTAINING THE SAME, A COMPOSITION CONTAINING THE SAME AND A USE OF SAID COMPOUNDS | FILECLO SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2024-09-05 | — | — | US | disclosed |
| EP-4380939-A1 | COMPOUNDS CONSTITUTING C20-MODIFIED SALINOMYCIN DERIVATIVES, A METHOD FOR OBTAINING THE SAME, A COMPOSITION CONTAINING THE SAME AND A USE OF SAID COMPOUNDS | Fileclo Spolka Z Ograniczona Odpowiedzialnoscia (PL) | 2024-06-12 | — | — | EP | disclosed |
| CN-118103377-A | Compounds constituting C20 modified salinomycin derivatives, process for obtaining the compounds, compositions containing the compounds and uses of said compounds | 菲莱克洛有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117903036-A | Synthesis and application of novel FXR (FXR) agonist | 厦门市博瑞来医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023012323-A1 | COMPOUNDS CONSTITUTING C20-MODIFIED SALINOMYCIN DERIVATIVES, A METHOD FOR OBTAINING THE SAME, A COMPOSITION CONTAINING THE SAME AND A USE OF SAID COMPOUNDS | FILECLO SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2023-02-09 | — | — | WO | disclosed |
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | KI PHARMACEUTICALS, LLC | 2021-08-19 | — | — | US | disclosed |
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | CYP19A1, PGR, CYP21A2 | MAPT 4155/4885ALDH1A1 746/4885POLB 3334/4885 |
| US-20090281087-A1 | Compounds II | GPR119, FABP4, LIPC | MAPT 4470/4885ALDH1A1 2717/4885POLB 3042/4885 |
| US-20240294541-A1 | COMPOUNDS CONSTITUTING C20-MODIFIED SALINOMYCIN DERIVATIVES, A METHOD FOR OBTAINING THE SAME, A COMPOSITION CONTAINING THE SAME AND A USE OF SAID COMPOUNDS | MRPS22, MRPS27, DHPS | MAPT 4251/4885ALDH1A1 2884/4885POLB 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.